Abstract 15: Glycemic and body weight responses to oral semaglutide in the PIONEER trial program

Case: The PIONEER phase 3 program investigated glycemic response and other efficacy endpoints in patients (pts) with type 2 diabetes randomized to the glucagon-like peptide-1 analog oral semaglutide (sema; 3, 7 or 14 mg once daily), placebo (pbo) or an active comparator (empagliflozin [empa] 25 mg,...

Descripción completa

Detalles Bibliográficos
Autores principales: Kumar, K B Sharan, Dungan, Kathleen M, Hertz, Christin L, Mellibin, Linda, Nielsen, Morten Abildlund, Sorrig, Rasmus, Woo, Vincent C, Vilsboll, Tina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer - Medknow 2022
Materias:
Abstracts … Esicon 2021
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9067785/
http://dx.doi.org/10.4103/2230-8210.342129

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9067785/
http://dx.doi.org/10.4103/2230-8210.342129

Ejemplares similares